Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.

BACKGROUND Urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) play essential roles in tumor invasion and metastasis. High levels of both uPA and PAI-1 are associated with poor prognosis in breast cancer patients. To confirm the prognostic value of uPA and PAI-1 in primary breast cancer, we reanalyzed individual patient data provided by members of the European Organization for Research and Treatment of Cancer-Receptor and Biomarker Group (EORTC-RBG). METHODS The study included 18 datasets involving 8377 breast cancer patients. During follow-up (median 79 months), 35% of the patients relapsed and 27% died. Levels of uPA and PAI-1 in tumor tissue extracts were determined by different immunoassays; values were ranked within each dataset and divided by the number of patients in that dataset to produce fractional ranks that could be compared directly across datasets. Associations of ranks of uPA and PAI-1 levels with relapse-free survival (RFS) and overall survival (OS) were analyzed by Cox multivariable regression analysis stratified by dataset, including the following traditional prognostic variables: age, menopausal status, lymph node status, tumor size, histologic grade, and steroid hormone-receptor status. All P values were two-sided. RESULTS Apart from lymph node status, high levels of uPA and PAI-1 were the strongest predictors of both poor RFS and poor OS in the analyses of all patients. Moreover, in both lymph node-positive and lymph node-negative patients, higher uPA and PAI-1 values were independently associated with poor RFS and poor OS. For (untreated) lymph node-negative patients in particular, uPA and PAI-1 included together showed strong prognostic ability (all P<.001). CONCLUSIONS This pooled analysis of the EORTC-RBG datasets confirmed the strong and independent prognostic value of uPA and PAI-1 in primary breast cancer. For patients with lymph node-negative breast cancer, uPA and PAI-1 measurements in primary tumors may be especially useful for designing individualized treatment strategies.

[1]  H. Höfler,et al.  Invasion marker PAI‐1 remains a strong prognostic factor after long‐term follow‐up both for primary breast cancer and following first relapse , 1999, Breast Cancer Research and Treatment.

[2]  Daniel F. Hayes,et al.  Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful? , 2004, Breast Cancer Research and Treatment.

[3]  C. Sweep,et al.  Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. , 2001, Journal of the National Cancer Institute.

[4]  N. Brünner,et al.  S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  N. Brünner,et al.  The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival. , 2000, Cancer research.

[6]  N. Brünner,et al.  The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. , 2000, Cancer research.

[7]  V. Bécette,et al.  Dissemination risk index based on plasminogen activator system components in primary breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  B. Asselain,et al.  Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study , 1999, British Journal of Cancer.

[9]  J. Foekens,et al.  Clinical relevance of the urokinase plasminogen activator system in breast cancer , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[10]  N. Brünner,et al.  External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. , 1998, British Journal of Cancer.

[11]  J. Foekens,et al.  Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Skobe,et al.  Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization , 1998, Nature Medicine.

[13]  M. Duffy,et al.  Urokinase Plasminogen Activator: a Prognostic Marker in Breast Cancer including Patients with Axillary Node-negative Disease Materials and Methods Methods Enzymes and Protein Markers , 1997 .

[14]  F. Spyratos,et al.  Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods. , 1998, British Journal of Cancer.

[15]  G. Huet,et al.  Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  P. Carmeliet,et al.  Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation , 1997, Nature Genetics.

[17]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[18]  H. Höfler,et al.  Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy , 1997, Thrombosis and Haemostasis.

[19]  N. Brünner,et al.  Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  A. Geurts-Moespot,et al.  A Sensitive and Robust Assay for Urokinase and Tissue-Type Plasminogen Activators (Upa and Tpa) and Their Inhibitor Type I (Pai-1) in Breast Tumor Cytosols , 1997, The International journal of biological markers.

[21]  R. Bast,et al.  Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.

[22]  Steingrimur Stefansson,et al.  The serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectin , 1996, Nature.

[23]  D. Loskutoff,et al.  Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? , 1996, The Journal of cell biology.

[24]  N. Brünner,et al.  Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop. , 1996, European journal of cancer.

[25]  M. Fernö,et al.  Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay. , 1996, European journal of cancer.

[26]  M. Duffy,et al.  Proteases as prognostic markers in cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[28]  J. Foekens,et al.  Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. , 1995, Journal of the National Cancer Institute.

[29]  D. Casciato.  Manual of Clinical Oncology , 1995 .

[30]  K. Ulm,et al.  Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. , 1994, Cancer research.

[31]  Giampietro Gasparini,et al.  Erratum: “Evaluating the Potential Usefulness of New Prognostic and Predictive Indicators in Node-Negative Breast Cancer Patients,” , 1993 .

[32]  N. Brünner,et al.  High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. , 1993, Cancer research.

[33]  W. McGuire,et al.  Prognostic factors and therapeutic decisions in axillary node-negative breast cancer. , 1992, Annual review of medicine.

[34]  F Pozza,et al.  Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. , 1993, Journal of the National Cancer Institute.

[35]  W. McGuire,et al.  Prognostic factors and treatment decisions in axillary-node-negative breast cancer. , 1992, The New England journal of medicine.

[36]  Mike Clarke,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992 .

[37]  Anthony Howell,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .

[38]  Early Breast Cancer Trialists' Collaborative Group.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.

[39]  A. D. Schryver,et al.  Systemic treatment of early breast-cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women: 1 , 1992 .

[40]  F. Jänicke,et al.  Clinical Relevance of the Urokinase-Type and Tissue-Type Plasminogen Activators and of Their Type 1 Inhibitor in Breast Cancer , 1991, Seminars in thrombosis and hemostasis.

[41]  M. Duffy,et al.  Urokinase‐plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report , 1988, Cancer.

[42]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[43]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.